Skip to main content

Advertisement

Log in

Different expression of FoxM1 in human benign and malignant pleural effusion

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aims of this study were as follows: to analyze the forkhead box M1 (FoxM1) expression in benign and malignant pleural effusion by reverse transcription-polymerase chain reaction assay (RT-PCR); to explore the role of FoxM1 in formation and progress in malignant pleural effusion, and whether there is significant difference in expression level of FoxM1 between benign and malignant pleural effusion; to seek a gene marker diagnostically useful to identify benign and malignant pleural effusion in diagnosis and treatment of pleural effusion; and to collect expression level data of FoxM1 in 23 malignant pleural effusion samples (17 adenocarcinoma samples, four squamous carcinoma samples and two small cell lung carcinoma samples) and 15 benign pleural effusion samples (11 inflammatory pleural effusions, two transudates, two tuberculous pleural effusions) by RT-PCR. Among all 38 samples, average FoxM1 expression level of benign pleural effusions is (235.09 ± 59.99), while malignant pleural effusions (828.77 ± 109.76). Among 23 malignant samples, average FoxM1 expression level is (529.27 ± 75.85) in samples without cytological diagnostic evidence, while (1,218.12 ± 167.21) in samples with cytological diagnostic evidence. Differences of FoxM1 expression level between benign pleural effusions and malignant ones have statistical significance. There is an area of 0.881 under the receiver-operating characteristic curve, which verifies the accuracy of using FoxM1 expression level as diagnostic index to identify benign and malignant pleural effusions. According to our study, diagnostic sensitivity and specificity for FoxM1 expression level at 418.1 were 82.6 and 86.7 %, respectively, while 47.8 and 100 %, respectively, at 768.7. FoxM1 expression level in malignant pleural effusions is significantly higher than in benign ones. This study provides a new approach in clinical diagnosis, with FoxM1 as a specific molecule marker to identify benign and malignant pleural effusions. FoxM1 expression level could provide evidence for diagnosis and treatment of malignant pleural effusions and lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Reference

  1. Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators [J]. Mol Cell Biol. 2004;24(7):2649–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Laoukili J, Kooistra MR, Bras A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability [J]. Nat Cell Biol. 2005;7(2):126–36.

    Article  CAS  PubMed  Google Scholar 

  3. Kalinichenko VV, Major ML, Wang X, et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the pl9ARF tumor suppressor [J]. Genes Dev. 2004;18:830–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Kim IM, Ackerson T, Ramakrishna S, et al. The Forkhead Box M1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer [J]. Cancer Res. 2006;66:2153–61.

    Article  CAS  PubMed  Google Scholar 

  5. Liu YQ, Guo RH, Liu LK, et al. Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC) [J]. Chin J Oncol. 2011;33(6):426–30.

  6. Zhou L, Zhang PH, Xu X, et al. Role of inhibition of transcription factor fockhead box M1 expression by RNA interference in the proliferation and invasiveness of non-small cell lung cancer cells [J]. Natl Med J China. 2009;89(34):2424–28.

  7. Wang WX, Chen SX, Wen JF, et al. Expression and metastasis prognosis of CD44V6 MMP2, MMP9, TIMP1 and TIMP2 in non-small cell lung cancer [J]. China Med Eng. 2007;15(2):122–25, 130.

  8. Lok GTM, Chan DW, Liu VWS, Hui WWY, Leung THY, et al. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells [J]. PLoS ONE. 2011;6(8):e23790.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This report was supported by the Youth Research Foundation of Shanghai Municipal Health Bureau (20124Y194).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Huili Zhu or Chunxue Bai.

Additional information

Zhonghao Tang and Hongqing Li have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, Z., Li, H., Zhu, H. et al. Different expression of FoxM1 in human benign and malignant pleural effusion. Med Oncol 32, 312 (2015). https://doi.org/10.1007/s12032-014-0312-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0312-1

Keywords

Navigation